Researchers from Isis Pharmaceuticals this week reported in vitro evidence on the existence of a new class of siRNA, which can promote target RNA reduction independent of both Argonaute and RISC.
The authors of the study, which appeared in Nucleic Acids Research, caution that much work remains to be done before the significance of these siRNAs can be established, however.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
